Tuberculosis Research Centre, India

Quick facts

Phase 3 pipeline

• BCG vaccine (Freeze-dried) · Immunology / Infectious Disease
  BCG vaccine stimulates the immune system to recognize and attack Mycobacterium tuberculosis by activating T-cell and macrophage-mediated immunity.
• Didanosine, Lamivudine, Nevirapine · Infectious Disease / Virology
  This is a fixed-dose combination of three nucleoside/non-nucleoside reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.
• Isoniazid with Ethambutol · Infectious Disease
  Isoniazid and ethambutol are bactericidal and bacteriostatic agents that inhibit mycobacterial cell wall and metabolic synthesis, respectively, to treat tuberculosis infection.
• Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol · Infectious Disease
  This is a fixed-dose combination of five anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and protein production, killing Mycobacterium tuberculosis through multiple mechanisms.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Tuberculosis Research Centre, India portfolio CI brief
• Tuberculosis Research Centre, India pipeline updates RSS